Clinical Commander

Back to dossier
cardio.hypertensive-emergency.acute-renovascular-flash-pulm-edema.v1PRODUCTION
cardio.hypertensive-emergency.acute-renovascular-flash-pulm-edema.v1

Acute renovascular flash pulmonary edema (Pickering syndrome)

cardiologyacuteadult
Hard-required inputs
0 / 11
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Pickering syndrome = bilateral RAS (or unilateral RAS with single functioning kidney) + RAAS hyperactivation → severe HTN + recurrent flash pulmonary edema episodes. Acute management: standard flash pulm edema bundle (NTG + IV loop + NIPPV per 3CPO PMID 18768944) WITHOUT ACEi/ARB (precipitous AKI risk). Definitive: renal artery angioplasty/stenting in flash-pulm-edema phenotype per CORAL subgroup analyses (PMID 24245566); FMD → stenting indicated.

Inputs
4
Actions
0
Advance rule
Set
Advance when

flash pulm edema phenotype confirmed + Pickering suspicion documented

Patient inputs (14)

First-line non-invasive RAS screen — peak systolic velocity >180 cm/s + RAR >3.5 (sensitivity ~85%, specificity ~92% per ACR appropriateness criteria); bedside-feasible after acute stabilization

Atherosclerotic RAS typical >55 with vascular disease; FMD typical 15-50, female-predominant; both can present with Pickering syndrome

Orthopnea + PND classic for cardiogenic flash edema vs ARDS

Trend critical — ACEi/ARB-induced Cr rise >30% within 1-2 wk = pathognomonic for bilateral RAS; baseline Cr drives revasc decision (CORAL excluded eGFR <30)

ACS overlap — flash pulm edema may herald MI, especially in atherosclerotic RAS phenotype with concurrent CAD

Bilateral infiltrates + cephalization confirm cardiogenic edema; baseline cardiomegaly suggests chronic HTN

Rule out STEMI overlap; LVH typical in chronic HTN (Pickering patients have decades of HTN)

EF + diastolic function (HFpEF common in Pickering — chronic HTN-induced); valvular function (rule out acute MR); LV mass for chronic HTN burden

O2 + NIPPV titration during flash edema episode; SpO2 <90 on RA typical

RR >25-30 + accessory muscle use → NIPPV; >35 + AMS → consider intubation

Goal SBP ↓ 25% in first hour; preserve perfusion (ACC/AHA 2025); resistant HTN typical baseline

Renin typically high in renovascular HTN; ARR helps differentiate from primary aldosteronism (low renin) — order after acute stabilization

CTA preferred for atherosclerotic RAS visualization; MRA if CTA contraindicated (eGFR concern); MRA shows characteristic "string of beads" in FMD

BNP >500 LR+ 8.1 for AHF (Maisel NEJM 2002 PMID 12124404); confirms cardiogenic etiology

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationalsevereacei_arb_induced_aki_in_pickering
    Cr rise >30% within 1-2 wk of starting/escalating ACEi/ARB — pathognomonic reveal for bilateral RAS or unilateral RAS with single functioning kidney
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_flash_pulm_edema_episodes
    ≥2 flash pulm edema episodes within 12 months in patient with resistant HTN — Pickering phenotype mandates revascularization evaluation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecoral_revascularization_decision_in_pickering
    Confirmed RAS + flash-pulm-edema phenotype OR resistant HTN OR refractory CHF — multidisciplinary revascularization decision per CORAL subgroup data
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefmd_vs_atherosclerotic_etiology_differentiation
    Determining FMD (younger women, "string of beads," good revasc response) vs atherosclerotic RAS (older + vascular disease, ostial/proximal stenosis, mixed revasc response) — drives revasc approach + surveillance
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

Pickering syndrome — acute flash edema bundle (NTG/loop/NIPPV) + chronic CCB-based regimen + AVOID ACEi/ARB in bilateral RAS + revascularization decision
axis: pickering_renovascular_flash_edema_acute_and_chronic
Selected axis "Pickering syndrome — acute flash edema bundle (NTG/loop/NIPPV) + chronic CCB-based regimen + AVOID ACEi/ARB in bilateral RAS + revascularization decision" by default fallback (first axis)
  • nitroglycerin
    first line
    organic_nitrate
    5-10 µg/min IV, titrate by 5 µg/min q5min up to 200 µg/min • IV • continuous
    triggers: acute_flash_pulmonary_edema_in_pickering
    ACC/AHA 2025 first-line — preload + afterload reduction; rapid onset; AVOID if SBP <90 / RV infarct / PDE5 within 24-48h
    rxcui 4917
  • furosemide
    first line
    loop_diuretic
    40-80 mg IV bolus (or 1-2× home daily dose if chronic HF) per DOSE • IV • q12h or continuous infusion 5-20 mg/h
    triggers: acute_flash_edema_with_volume_overload
    DOSE trial PMID 21366472 — high-dose IV; reassess UOP at 2h; maintenance for chronic Pickering with diuretic-responsive volume
    rxcui 4603
  • amlodipine
    first line
    DHP_CCB
    Amlodipine 5-10 mg PO daily • PO • daily
    triggers: chronic_pickering_BP_control, safe_in_any_RAS
    CCB safe in any RAS (no kidney perfusion risk like ACEi/ARB); ACC/AHA 2025 first-line for Pickering chronic management
    rxcui 17767
  • nicardipine
    second line
    DHP_CCB
    5 mg/h IV titrate by 2.5 mg/h q5-15 min • IV • continuous
    triggers: flash_edema_BP_control_after_NTG_max, nitrate_intolerant_or_resistant_HTN
    Add when NTG alone insufficient; safe with HF (does not worsen LV function); CCB-class consistent with chronic plan
    rxcui 7396
  • labetalol
    comorbidity specific
    mixed_alpha_beta_blocker
    20 mg IV q10 min OR 200 mg PO BID maintenance • IV or PO • bolus or BID
    triggers: concurrent_tachycardia_or_chronic_oral_tier
    Useful adjunct; cautious use in acute decompensated HF
    rxcui 6185
  • minoxidil
    add on
    arteriolar_vasodilator_K_channel_opener
    2.5-5 mg PO daily, titrate to 10-40 mg daily • PO • daily-BID
    triggers: resistant_chronic_pickering_after_max_CCB_diuretic, pre_revascularization_bridge
    Reserved for resistant HTN; ALWAYS combine with BB + loop diuretic (reflex tachycardia + Na/H2O retention); useful bridge to revasc
    rxcui 6984
  • NIPPV (CPAP 8-10 cmH2O or BiPAP 12/5)
    first line
    non_invasive_ventilation
    CPAP 8-10 cmH2O OR BiPAP IPAP 12 / EPAP 5; titrate to SpO2 >92 • mask • continuous
    triggers: flash_pulm_edema_with_respiratory_distress
    3CPO trial PMID 18768944 — NIPPV reduces intubation rate vs standard O2 in cardiogenic pulm edema
  • Renal artery angioplasty + stenting
    first line
    revascularization
    Per IR / vascular surgery; stent in atherosclerotic; angioplasty alone often durable in FMD • endovascular • definitive procedure
    triggers: recurrent_flash_pulm_edema_phenotype, fmd_with_severe_stenosis, medically_refractory_resistant_htn
    CORAL PMID 24245566 — null overall but flash-pulm-edema subgroup analyses suggest benefit; AHA 2014 Scientific Statement supports revasc in flash edema phenotype + resistant HTN; FMD has high success with angioplasty alone
  • AVOID ACE inhibitors / ARBs in BILATERAL RAS
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: bilateral_RAS_confirmed, unilateral_RAS_with_single_functioning_kidney
    Pathophysiology: efferent arteriole dilation → loss of GFR-maintaining pressure → precipitous AKI; ACEi/ARB challenge often the diagnostic reveal; safe in unilateral RAS with normal contralateral kidney + close Cr monitoring
  • AVOID nitroprusside if eGFR <30
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: egfr_lt_30_or_anuria
    Cyanide accumulation risk; CKD common in chronic Pickering due to chronic ischemic nephropathy
  • AVOID isolated diuretic without vasodilator in acute episode
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: acute_flash_pulm_edema_with_severe_HTN
    Diuretic alone in HTN-driven flash edema = incomplete unloading; preload + afterload reduction with NTG is FIRST move (ACC/AHA 2025)

outpatient playbook — drug actions (2)

  1. 1. continue CCB-based regimen + statin/ASA if atherosclerotic
    rxcui 17767
    Per maintenance regimen • PO • as scheduled
    trigger: Stable maintenance
    ACC/AHA 2025 + AHA 2014 PMID 24685930
  2. 2. cautious ARB trial post-revasc with monitoring
    rxcui 69749
    Valsartan up-titrate with q1-2wk Cr monitoring • PO • daily
    trigger: Successful revasc + anatomy permits
    Post-revasc benefit returns; close monitoring

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Recurrent flash pulmonary edema episodes + resistant HTN despite ≥3 antihypertensives (incl diuretic) — Pickering syndrome screen; AKI (Cr rise >30%) within 1-2 wk of starting ACEi/ARB — pathognomonic for bilateral RAS or unilateral RAS with single functioning kidney; Asymmetric kidney size on prior imaging (>1.5 cm difference) or atrophic kidney — RAS suspicion.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute renovascular flash pulmonary edema (Pickering syndrome)** (cardio.hypertensive-emergency.acute-renovascular-flash-pulm-edema.v1).
Scope: Pickering syndrome = bilateral RAS (or unilateral RAS with single functioning kidney) + RAAS hyperactivation → severe HTN + recurrent flash pulmonary edema episodes. Acute management: standard flash pulm edema bundle (NTG + IV loop + NIPPV per 3CPO PMID 18768944) WITHOUT ACEi/ARB (precipitous AKI risk). Definitive: renal artery angioplasty/stenting in flash-pulm-edema phenotype per CORAL subgroup analyses (PMID 24245566); FMD → stenting indicated.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Pickering syndrome — acute flash edema bundle (NTG/loop/NIPPV) + chronic CCB-based regimen + AVOID ACEi/ARB in bilateral RAS + revascularization decision**.
1. nitroglycerin 5-10 µg/min IV, titrate by 5 µg/min q5min up to 200 µg/min IV continuous (organic_nitrate, first line) — ACC/AHA 2025 first-line — preload + afterload reduction; rapid onset; AVOID if SBP <90 / RV infarct / PDE5 within 24-48h
2. furosemide 40-80 mg IV bolus (or 1-2× home daily dose if chronic HF) per DOSE IV q12h or continuous infusion 5-20 mg/h (loop_diuretic, first line) — DOSE trial PMID 21366472 — high-dose IV; reassess UOP at 2h; maintenance for chronic Pickering with diuretic-responsive volume
3. amlodipine Amlodipine 5-10 mg PO daily PO daily (DHP_CCB, first line) — CCB safe in any RAS (no kidney perfusion risk like ACEi/ARB); ACC/AHA 2025 first-line for Pickering chronic management
4. nicardipine 5 mg/h IV titrate by 2.5 mg/h q5-15 min IV continuous (DHP_CCB, second line) — Add when NTG alone insufficient; safe with HF (does not worsen LV function); CCB-class consistent with chronic plan
5. labetalol 20 mg IV q10 min OR 200 mg PO BID maintenance IV or PO bolus or BID (mixed_alpha_beta_blocker, comorbidity specific) — Useful adjunct; cautious use in acute decompensated HF
6. minoxidil 2.5-5 mg PO daily, titrate to 10-40 mg daily PO daily-BID (arteriolar_vasodilator_K_channel_opener, add on) — Reserved for resistant HTN; ALWAYS combine with BB + loop diuretic (reflex tachycardia + Na/H2O retention); useful bridge to revasc
7. NIPPV (CPAP 8-10 cmH2O or BiPAP 12/5) CPAP 8-10 cmH2O OR BiPAP IPAP 12 / EPAP 5; titrate to SpO2 >92 mask continuous (non_invasive_ventilation, first line) — 3CPO trial PMID 18768944 — NIPPV reduces intubation rate vs standard O2 in cardiogenic pulm edema
8. Renal artery angioplasty + stenting Per IR / vascular surgery; stent in atherosclerotic; angioplasty alone often durable in FMD endovascular definitive procedure (revascularization, first line) — CORAL PMID 24245566 — null overall but flash-pulm-edema subgroup analyses suggest benefit; AHA 2014 Scientific Statement supports revasc in flash edema phenotype + resistant HTN; FMD has high success with angioplasty alone
9. AVOID ACE inhibitors / ARBs in BILATERAL RAS AVOID N/A N/A (do_not_use, contraindication substitute) — Pathophysiology: efferent arteriole dilation → loss of GFR-maintaining pressure → precipitous AKI; ACEi/ARB challenge often the diagnostic reveal; safe in unilateral RAS with normal contralateral kidney + close Cr monitoring
10. AVOID nitroprusside if eGFR <30 AVOID N/A N/A (do_not_use, contraindication substitute) — Cyanide accumulation risk; CKD common in chronic Pickering due to chronic ischemic nephropathy
11. AVOID isolated diuretic without vasodilator in acute episode AVOID N/A N/A (do_not_use, contraindication substitute) — Diuretic alone in HTN-driven flash edema = incomplete unloading; preload + afterload reduction with NTG is FIRST move (ACC/AHA 2025)

Setting playbook (outpatient) — Long-term cardiology + nephrology + vascular surveillance — secondary prevention for atherosclerotic etiology, FMD vascular bed surveillance for FMD etiology, revascularization durability assessment, BP <130/80, recurrence prevention
12. continue CCB-based regimen + statin/ASA if atherosclerotic Per maintenance regimen PO as scheduled — Stable maintenance (ACC/AHA 2025 + AHA 2014 PMID 24685930)
13. cautious ARB trial post-revasc with monitoring Valsartan up-titrate with q1-2wk Cr monitoring PO daily — Successful revasc + anatomy permits (Post-revasc benefit returns; close monitoring)

Non-pharmacologic actions:
- Sodium maintenance
- Cardiac rehab maintenance phase
- Annual flu + COVID + pneumococcal vaccinations
- FMD: vascular FMD elsewhere surveillance (cervicocephalic, mesenteric, coronary FMD)

AVOID / contraindication checks:
- NTG_avoid_sbp_lt_90 (ACC/AHA 2025)
- NTG_avoid_pde5_within_24 48h (ACC/AHA 2025)
- Nitroprusside_avoid_egfr_lt_30_cyanide (ACC/AHA 2025)
- ACEi_ARB_avoid_in_bilateral_RAS_or_single_functioning_kidney_RAS (AHA 2014 PMID 24685930)
- Isolated_diuretic_avoid_in_HTN_flash_edema_incomplete_unloading (ACC/AHA 2025)
- Minoxidil_always_with_BB_and_loop_diuretic (ACC/AHA 2025)
- Contrast_load_caution_in_CKD_pre_revasc_imaging (KDIGO 2024)

Monitoring

Regimen monitoring:
- arterial line q5-15min BP acute phase (ACC/AHA 2025)
- continuous SpO2 target gt 92 (ESC 2021 HF)
- hourly UOP acute (ACC/AHA 2025)
- serial troponin q6h x 3 to rule out ACS (ACC/AHA 2025)
- BMP q6h acute then q1-2wk chronic for Cr trend (CORAL PMID 24245566)
- daily weight and strict I O (ESC 2021 HF)
- echo at 24-48h for EF and diastolic function (ESC 2021 HF)
- pre revasc CTA or MRA renal arteries (AHA 2014 PMID 24685930)
- post revasc BP log and BMP at 1wk then quarterly (CORAL)

Setting (outpatient) monitoring:
- Quarterly BP + weight
- Annual echo + renal Doppler
- q1-2wk Cr if any RAAS modulator change

Follow-up plan: Outpatient: revascularization decision (vascular surgery + IR + nephrology multidisciplinary); long-term BP control with CCB-based regimen + diuretic ± minoxidil + ARB cautious trial post-revasc if anatomy permits; statin + ASA for atherosclerotic RAS (secondary prevention); FMD: lifelong surveillance for vascular FMD elsewhere (cervicocephalic, mesenteric); 1-week follow-up; cardiac rehab if first HF episode
- Close-out criterion: revasc decision finalized + chronic regimen + 1-wk follow-up booked

Monitoring phase: Arterial line + q5-15 min BP; continuous SpO2 + ECG; hourly UOP; serial troponin q6h × 3; BMP q6h (especially if any RAAS modulation tried); daily weight + I/O; echo at 24-48h; pre-revasc anatomy CTA/MRA review

Disposition

Current setting: outpatient — Long-term cardiology + nephrology + vascular surveillance — secondary prevention for atherosclerotic etiology, FMD vascular bed surveillance for FMD etiology, revascularization durability assessment, BP <130/80, recurrence prevention

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.resistant.v1 + cardio.hfpef.core.v1 (chronic HTN burden)

Escalation triggers (move to higher acuity):
- Restenosis on Doppler → repeat imaging + revasc consideration
- Symptom recurrence → reassessment
- Cr rise on RAAS modulator → discontinue + reassess

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] Cr rise >30% within 1-2 wk of starting/escalating ACEi/ARB — pathognomonic reveal for bilateral RAS or unilateral RAS with single functioning kidney
- [SEVERE] ≥2 flash pulm edema episodes within 12 months in patient with resistant HTN — Pickering phenotype mandates revascularization evaluation
- [SEVERE] Confirmed RAS + flash-pulm-edema phenotype OR resistant HTN OR refractory CHF — multidisciplinary revascularization decision per CORAL subgroup data

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) + ESC 2021 HF Guideline (PMID 34447992) + AHA 2014 RAS Scientific Statement (PMID 24685930) + CORAL trial (PMID 24245566) [PMID:38316810](https://pubmed.ncbi.nlm.nih.gov/38316810/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 34447992) [PMID:34447992](https://pubmed.ncbi.nlm.nih.gov/34447992/)
- Cited evidence (PMID 18768944) [PMID:18768944](https://pubmed.ncbi.nlm.nih.gov/18768944/)
- Cited evidence (PMID 21366472) [PMID:21366472](https://pubmed.ncbi.nlm.nih.gov/21366472/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) + ESC 2021 HF Guideline (PMID 34447992) + AHA 2014 RAS Scientific Statement (PMID 24685930) + CORAL trial (PMID 24245566) — PMID:38316810
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 34447992) — PMID:34447992
  • Cited evidence (PMID 18768944) — PMID:18768944
  • Cited evidence (PMID 21366472) — PMID:21366472